A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-05

Study Completion Date

2026-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the bioavailability, safety and tolerability of Torasemide 10 mg tablets (Berlin-Chemie AG), compared to Unat® 10 tablets (Viatris Healthcare GmbH) in healthy adult participants under fasting conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions

NCT04921566

Bioequivalence

COMPLETED PHASE1

Bioavailability Study of Torsemide Tablets Under Fasting Conditions

NCT00653549

To Determine Bioequivalence Under Fasting Conditions

COMPLETED PHASE1

Bioavailability Study of Torsemide Tablets Under Fed Conditions

NCT00654043

Healthy

COMPLETED PHASE1

Bioequivalency Study of Torsemide Tablets Under Fasting Conditions

NCT00602303

Edema

COMPLETED NA

Bioequivalency Study of Torsemide Tablets Under Fed Conditions

NCT00602615

Edema

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this Phase I study, the test medication Torasemide 10 mg tablets (Berlin-Chemie AG) is compared to Unat® 10 tablets (Viatris Healthcare GmbH) in terms of bioequivalence of the tested formulations under fasting conditions

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Adult Male and Female Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Prospective, randomized, open-lable, , single-dose, two-period, two-treatment, two-sequence, crossover bioequivalence study

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Torasemide 10 mg tablet

Single dose administration (10 mg) with 240 mL of water under fasting conditions

Group Type EXPERIMENTAL

Torasemide tablet 10 mg

Intervention Type DRUG

Tablets by Berlin-Chemie AG (Germany)

Unat® 10 (Torasemide) tablets (Viatris Healthcare GmbH)

Single dose administration (10 mg) with 240 mL of water under fasting conditions

Group Type EXPERIMENTAL

Unat® 10 tablets (Torasemide 10 mg)

Intervention Type DRUG

Tablets by Viatris Healthcare GmbH (Germany)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Torasemide tablet 10 mg

Tablets by Berlin-Chemie AG (Germany)

Intervention Type DRUG

Unat® 10 tablets (Torasemide 10 mg)

Tablets by Viatris Healthcare GmbH (Germany)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male and female individuals aged 18 to 55 years inclusive at the time of signing the ICF.
2. Body weight ≥50 kg and Body Mass Index (BMI) between ≥18.5 and \<30.0 kg/m2.
3. A healthy individual as determined by the Investigator based on medical history and results of standard clinical, laboratory and instrumental methods of examination (individuals with not clinically significant \[NCS\] abnormalities are eligible for the study).
4. A non-smoker (for at least 3 months before screening), verified by the cotinine test at screening.
5. A negative urine pregnancy test (rapid test) within 24 h before the first IMP dose for female individuals of childbearing potential. Postmenopausal (no menses for at least 1 year) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) females are exempted from the requirement.
6. Individuals with preserved reproductive potential should agree to use, with their partner, adequate contraception throughout the study and for 30 days thereafter (contraceptive methods with reliability greater than 90%: cervical caps with spermicide, diaphragms with spermicide, condoms with intravaginal spermicide, non-hormonal intrauterine devices), or true sexual abstinence.
7. Capable of understanding the ICF and giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and the study protocol.

Exclusion Criteria

1. Known hypersensitivity or intolerance to torasemide, other sulfonylureas, or any other excipient of the IMPs.
2. History of renal failure with anuria.
3. History of hepatic precoma, coma.
4. History of hypotension.
5. History of hypovolemia.
6. History of hyponatremia and/or hypokalemia.
7. History of substantial micturition disorders (e.g. due to prostatic hypertrophy).
8. History of gout.
9. History of cardiac arrhythmias (e.g. SA block, 2nd or 3rd degree AV block).
10. History of latent or manifest diabetes mellitus or any form of hyperglycemia.
11. History of pathological changes in the acid-base balance.
12. History of pathological changes in the blood count (e.g. thrombocytopenia, anemia in patients without renal insufficiency).
13. History of abnormally high (≥190 mg/dL \[≥4.9 mmol/L\]) low-density lipoprotein (LDL) cholesterol levels within 3 months before the first IMP dose.
14. Abnormally high triglycerides levels (\>150 mg/dL \[\>1.7 mmol/L\]) within 3 months before the first IMP dose.
15. History of renal insufficiency (creatinine clearance between 20 mL and 30 mL/min and/or serum creatinine concentrations between 3.5 mg/dL and 6 mg/dL) due to nephrotoxic substances.
16. History of other clinically significant cardiovascular, respiratory, renal, hepatic, endocrine, metabolic, gastrointestinal, hematological, genito-urinary disease, bleeding disorders, neurological or psychiatric pathology, oncologic disease, autoimmune disease, dermatological disease or other chronic disease, that makes the individual ineligible for the study.
17. Acute infectious diseases (e.g. influenza, acute respiratory bacterial or viral infections incl. COVID-19) less than 4 weeks before the first IMP dose.
18. Hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
19. Systolic blood pressure \< 90 mmHg or ≥ 130 mmHg and/or diastolic blood pressure \< 60 mmHg or ≥ 85 mmHg.
20. Heart rate \< 60 or \> 100 beats per minute.
21. The presence of any other condition which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
22. Use of the following medications within the relevant period before the first IMP dose:

1. Use of medications (including hormonal contraceptives) that have a significant effect on circulatory dynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, diuretics, etc.) within 2 months before the first IMP dose.
2. Use of depot-forms of any medications within 3 months before the first IMP dose.
3. Use of any other prescribed or non-prescribed medication, herbal remedies, vitamins and minerals within 2 weeks before the first IMP dose or longer (at least 5 elimination half-lives) if the medication has a long half-life.
23. Female individuals who are lactating.
24. Female individuals of childbearing potential, having unprotected sexual intercourse with any unsterilized male partner (i.e., a man who is not sterilized by vasectomy for at least 6 months) within 30 days before the first IMP dose.
25. Blood donation/blood loss \>450 mL within 60 days or apheresis donation within 30 days before the first IMP dose.
26. Dehydration (e.g. due to diarrhea, vomiting, or other causes) within the last 48 h before the first IMP dose.
27. Positive test result for COVID-19 rapid antigen test at admission to the Study Site.
28. Positive test results for HIV or hepatitis B (HBsAg, anti-HBc) or C (anti-HCV) or syphilis at screening.
29. History of drug or alcohol abuse within 1 year before the screening. Alcohol abuse is defined as regular intake of more than 10 units of alcohol a week (1 unit equivalent to 200 mL of dry wine or 50 mL of strong alcoholic drinks or 500 mL of beer).
30. Positive screen for drugs or alcohol at screening.
31. Individuals who have been on a special diet (for whatever reason, e.g. vegetarians or hypocaloric diet \[\< 1000 kcal/day\]) within the 28 days before the first IMP dose and throughout the study.
32. Intake of methylxanthine-containing substances (e.g., coffee, tea, chocolate, cocoa, energy drinks, cola) as well as citrus fruits and cranberry (including juices, fruit drinks, etc.) within the last 48 h before the first IMP dose.
33. Intake of food or beverages containing poppy seeds within 72 h before the first IMP dose.
34. Excessive consumption (defined as greater than 6 servings - 1 serving being approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks or other caffeinated beverages per day within 2 weeks before the first IMP dose.
35. Mental, physical and other reasons that do not allow the individual, according to Investigator's opinion, to assess their behavior adequately, to follow correctly the requirements of the clinical study protocol and to assess the expected risks and possible discomfort.
36. Participation in another clinical study (except if no investigational product was administered) within 3 months before the first IMP dose.
37. Employee or family member of the Sponsor or the involved Contract Research Organization (CRO) or the Study Site.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes